BioAdaptives, Inc. (BDPT) Stock Price & Analysis
BioAdaptives, Inc. (BDPT) — price $0.0012 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
BioAdaptives, Inc. · BDPT
BioAdaptives, Inc. develops and distributes plant and algal-based health and wellness products for humans and animals. The company operates in the consumer defensive sector, focusing on dietary supplements and related products.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0012 |
| Change on the day | 0.00% |
| Shares traded on the day | 1.61M |
Price & events
Other perspectives
Council score for BioAdaptives (BDPT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BioAdaptives (BDPT), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioAdaptives, Inc. (BDPT) is the company analyzed here. It employs 1 people. In Q2 FY2026 it reported revenue of $4,988 and net income of $150,090.
What do the latest results show for BioAdaptives (BDPT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $4,988.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $4,988 | $150,090 | $0.01 (diluted) |
| Q1 FY2026 | $5,514 | -$111,086 | -$0.01 (diluted) |
| Q4 FY2025 | $10,427 | -$823,482 | -$0.07 (diluted) |
| Q3 FY2025 | $4,632 | -$379,502 | -$0.04 (diluted) |
What are the financial strengths and risks for BioAdaptives (BDPT)?
Short answer · as of
The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 62.1% · current ratio 0.04.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 2, 2026
- Transactions
- 6
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 0
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BDPT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BDPT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BioAdaptives (BDPT)?
- BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research
- BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At Home Psilocybin Treatment
- BioAdaptives Highlights Michael Bisping's MyndMed(TM) Routine in UFC 331 Pre-Show Instagram Video
Investor Questions: BDPT Stock
These answers are editorial: 1 of these 1 answer is drawn from the BDPT research dossier (written Mar 18, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What does BioAdaptives, Inc. do?
BioAdaptives, Inc. formulates, markets, and distributes natural plant and algal-based health and wellness products for both humans and animals. The company focuses on dietary supplements and specialized formulations like PrimiCell, PluriPain, and Regen compounds. These products are sold directly to consumers and through partnerships with retailers and distributors.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 9 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com